Medigen Biotechnology (ROCO:3176) Interest Expense: NT$-23 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3176 Medigen Biotechnology Corp ROCO:3176
54 GF Score
Price NT$33.80
GF Value NT$49.74
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medigen Biotechnology Interest Expense?

Medigen Biotechnology ROCO:3176 +0.75% 54 Interest Expense is NT$-23 Mil as of Dec. 2025. GuruFocus rates ROCO:3176 with a GF Score™ of 54/100 and a GF Value™ of NT$49.74 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Medigen Biotechnology's interest expense for the three months ended in Dec. 2025 was NT$ -6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-23 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Medigen Biotechnology's Operating Income for the three months ended in Dec. 2025 was NT$ -158 Mil. Medigen Biotechnology's Interest Expense for the three months ended in Dec. 2025 was NT$ -6 Mil. Medigen Biotechnology did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Medigen Biotechnology  (ROCO:3176) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Medigen Biotechnology's Interest Expense for the three months ended in Dec. 2025 was NT$-6 Mil. Its Operating Income for the three months ended in Dec. 2025 was NT$-158 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2025 was NT$695 Mil.

Medigen Biotechnology's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Medigen Biotechnology did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Medigen Biotechnology Interest Expense Historical Data

* Premium members only.

The historical data trend for Medigen Biotechnology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology Interest Expense Chart

Medigen Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.07 -39.45 -55.86 -36.39 -23.12

Medigen Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.89 -5.87 -5.82 -5.69 -5.74
ROCO:3176
54GF Score
Medigen Biotechnology Corp ROCO:3176
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Biotechnology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of NT$-23 Mil mean?
Medigen Biotechnology (ROCO:3176) has a Interest Expense of NT$-23 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's Interest Expense too high?
Medigen Biotechnology's current Interest Expense is NT$-23 Mil. Overall, Medigen Biotechnology has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Interest Expense compare to VRTX and REGN?
Medigen Biotechnology's Interest Expense of NT$-23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current Interest Expense is NT$-23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$49.74, compared to a current price of NT$33.80 — trading 32% below its estimated fair value. The current Interest Expense is NT$-23 Mil. Medigen Biotechnology's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Interest Expense is NT$-23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued. The current stock price of NT$33.80 is trading 32% below its estimated GF Value™ of NT$49.74. GuruFocus considers Medigen Biotechnology to be Significantly Undervalued.

Key valuation signals for ROCO:3176:

  • Interest Expense: NT$-23 Mil
  • GF Value™: NT$49.74 vs. price of NT$33.80 (32% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
54GF Score

Get the complete analysis for ROCO:3176

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.80
Price
NT$49.74
GF Value